Marc Farhm All right, we will. before we really get started, we'll wait for a second here to let everybody join the session. But welcome back to the fifth annual Callen IO Summit. Hopefully the … [Read more...] about GRTS Transcript-Cowen 2021
Cancer
Gritstone Bio (GRTS) Makes History in a Historically Hopeless Setting
As mentioned in our last report, Gritstone Bio (GRTS) initially applied its next-generation heterologous (virus/sa-mRNA) vaccine technology to fight cancer. The thesis articulated by the founding … [Read more...] about Gritstone Bio (GRTS) Makes History in a Historically Hopeless Setting
Kintara Therapeutcis (NASDAQ: KTRA)….
Since our last article discussing Kintara Therapeutics (NASDAQ: KTRA) underappreciated value proposition to investors, CEO Saiid Zarrabian has solidified the company’s position for growth in 2021 and … [Read more...] about Kintara Therapeutcis (NASDAQ: KTRA)….
Bristol-Myers Squibb Positioned For Deep Penetration In the Multiple Myeloma Market
Introduction Bristol-Myers Squibb (NYSE: BMY) is a profitable global bio-pharmaceutical company targeting an array of serious diseases and unmet medical needs. Earlier this month BMY announced … [Read more...] about Bristol-Myers Squibb Positioned For Deep Penetration In the Multiple Myeloma Market
Potentially Lucrative Opportunities Amidst A Stock Market Bloodbath
Overview Wednesday October 24th, 2018 the stock market was slashed across the board with the DOW erasing all its gains for the year and dripping red. The Nasdaq was hit with equal force. Comments from … [Read more...] about Potentially Lucrative Opportunities Amidst A Stock Market Bloodbath
VSTM Overaction to Black Box Label Creates Buying Opportunity
For months Verastem Oncology (VSTM) investors have been eagerly awaiting the FDA's decision on it's lead product Duvelisib; a PI3K-δ (delta) and PI3K-γ (gamma) inhibitor that was granted Orphan Drug … [Read more...] about VSTM Overaction to Black Box Label Creates Buying Opportunity
Market Hasn’t Grasped the Magnitude of GALT Phase1b Keytruda Combo Study
Today September 20th Galectin Therapeutics (NASDAQ: GALT) announced promising results from their phase 1b clinical trial of GR-MD-02 and KEYTRUDA® in Advanced Melanoma and Expansion of the Trial. … [Read more...] about Market Hasn’t Grasped the Magnitude of GALT Phase1b Keytruda Combo Study
GR-MD-02: Keytrua’s Partner, Cancer’s Nemesis
Tumors excrete elevated level of galectin-3 Galectin-3 diminishes T-cells’ ability to kill tumor cells Galectin-3 aids in cancer progression GR-MD-02 is safe, effective, and … [Read more...] about GR-MD-02: Keytrua’s Partner, Cancer’s Nemesis
GALT is Primed for Acquisition or Partnership
Overview Galectin Therapeutics (NASDAQ GALT $5.96) is a leader in the development of a treatment for Non-Alcoholic SteatoHepatitis, an unmet medical need worth billions. Their star drug … [Read more...] about GALT is Primed for Acquisition or Partnership
You must be logged in to post a comment.